Becton, Dickinson & Co. (BDX) Reports In-Line Q1 EPS; Lowers FY12 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BDX Hot Sheet
Price: $198.91 -0.75%
Revenue Growth %: -13.4%
Financial Fact:
Revenues: 3.23B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -13.4%
Financial Fact:
Revenues: 3.23B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Becton, Dickinson & Co. (NYSE: BDX) reported Q1 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.88 billion.
Sees FY2012 EPS of $5.60-$5.70, versus prior guidance of $5.75-$5.85 and the consensus of $5.80.
For earnings history and earnings-related data on Becton, Dickinson & Co. (BDX) click here.
Sees FY2012 EPS of $5.60-$5.70, versus prior guidance of $5.75-$5.85 and the consensus of $5.80.
For earnings history and earnings-related data on Becton, Dickinson & Co. (BDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
